SECsense Logo

Clearmind Medicine Inc. Secures Patent - January 2025 SEC Form 6-K Report

$CMND
Form 6-K
Filed on: 2025-01-02
Source
Clearmind Medicine Inc. Secures Patent - January 2025 SEC Form 6-K Report

Here are the key insights extracted from the financial report of Clearmind Medicine Inc. as presented in the SEC Form 6-K:

  1. Filing Type: This document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC.
  2. Company Information:
  • Name: Clearmind Medicine Inc.
  • Address: 101 – 1220 West 6th Avenue, Vancouver, British Columbia.
  • Commission File Number: 001-41557.
  1. Reporting Period: The report is for the month of January 2025.
  2. Patent Announcement:
  • The report includes a press release dated January 2, 2025, announcing that Clearmind Medicine has been granted a patent for a treatment related to binge behavior by the Macau International Intellectual Property Office. This patent could be significant for the company's product development and market positioning.
  1. Incorporation of Information:
  • The initial paragraphs of the attached press release are incorporated by reference into the company's Registration Statements on Form F-3 and Form S-8. This implies that the information is relevant for investors and part of the ongoing disclosure obligations of the company.
  1. Exhibit Index:
  • Exhibit 99.1 contains the detailed press release regarding the patent.
  1. Signature:
  • The report is signed by Adi Zuloff-Shani, the Chief Executive Officer of Clearmind Medicine, indicating that the information presented has been authorized by the company's leadership.
  1. Compliance: The filing complies with the requirements of the Securities Exchange Act of 1934, underscoring the company's adherence to regulatory standards.

This report highlights a key milestone for Clearmind Medicine in securing intellectual property protection, which could enhance its competitive advantage in the pharmaceutical or therapeutic market.